Alcon has received US Food and Drug Administration (FDA) approval for Tryptyr (acoltremon ophthalmic solution) 0.003%, the company’s first approved prescription pharmaceutical since it became a publicly traded entity.

Tryptyr is a neuromodulator designed to stimulate the TRPM8 (transient receptor potential melastatin 8) cold-sensing receptors on corneal sensory nerves. Activation of these receptors is believed to enhance basal tear production by triggering trigeminal nerve signaling, although the precise mechanism of action remains undetermined.

Tryptyr will be provided in single-dose vials, with a recommended regimen of 1 drop per eye, twice daily. The medication should not be used while wearing contact lenses, but lenses may be reapplied 15 minutes after administration. 

Alcon plans to launch Tryptyr in the US market in the third quarter of 2025. Global market expansion is anticipated thereafter.